Onyx Biotec Board of Directors

Get the latest insights into the leadership at Onyx Biotec. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Sanjay Jain Managing Director
Mr. Harsh Mahajan Whole-time Director & CFO & CEO
Mr. Naresh Kumar Whole Time Director
Ms. Lakshya Jain Whole Time Director
Mr. Parmjeet Kaur Non Executive Director
Mr. Prince Preet Singh Independent Director
Mr. Vineet Singh Independent Director
Mr. Nitesh Garg Independent Director

Onyx Biotec Share price

ONYX

49.9

0.55 (-1.09%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:31 IST
BUYSELL
Today's High

51.00

Today's Low

49.30

52 Week Low

45.00

52 Week High

97.45

The current prices are delayed, login to your account for live prices

Onyx Biotec FAQs

The board at Onyx Biotec consists of experienced professionals, including Mr. Sanjay Jain , Mr. Harsh Mahajan , and others, overseeing the company’s strategic and corporate governance.

Directors at Onyx Biotec are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Sanjay Jain is the current chairman at Onyx Biotec.

Executive directors at Onyx Biotec are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Onyx Biotec adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Onyx Biotec, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.